PepLabo Download

Zepbound® and insomnia

Zepbound® is unusual among weight medicines in having a sleep indication: in the US it also carries approval for treating moderate or severe obstructive sleep apnea when obesity is present. So when sleep gets worse rather than better on treatment, the question is worth asking carefully. This page sets out what the official documents and trials say about sleep, what research suggests, and the night-time causes that are easy to overlook.

Published · Updated · Zepbound®: side effects by symptom · Written by the PepLabo editorial team

Sleep in the Zepbound® documents

The main US safety data for Zepbound® come from SURMOUNT-1 and SURMOUNT-2, two 72-week trials in adults with obesity or overweight. Their pooled table lists reactions reported by at least 2% of people on Zepbound® and more often than on placebo; insomnia, trouble falling asleep and sleep disturbance are not among them. [1] The Canadian monograph lowers the threshold to 1% for the same trials and still does not list insomnia. [3] In the EU there is no Zepbound® product; tirzepatide for weight and sleep apnea is sold as Mounjaro®, and its adverse reaction table does not include insomnia either. [4]

What the labels do contain is sleep data from the other direction. In the US label’s section 14.2, the two sleep apnea trials (published as SURMOUNT-OSA) enrolled 469 adults with obesity and moderate to severe sleep apnea, and Zepbound® improved sleep-related impairment on a standard questionnaire compared with placebo. [1] The Canadian monograph adds that sleep disturbance scores also improved at week 52. [3]

Sleep-related findings for Zepbound® / tirzepatide (checked 20-10-2026)
SourceInsomnia as a side effectSleep findings
US label, Table 1, SURMOUNT-1 and -2 [1]Not listedFatigue (includes lethargy, malaise) 5 / 6 / 7% on 5 / 10 / 15 mg vs 3% on placebo
US label, SURMOUNT-OSA trials [1]Reactions similar to weight trialsSleep-related impairment improved vs placebo; mean Epworth sleepiness score at entry about 10
Canadian monograph [3]Not listed (≥1% table)Sleep-related impairment and sleep disturbance improved vs placebo at week 52
EU, tirzepatide sold as Mounjaro® [4]Not listedSleep apnea trial results described in section 5.1
NEJM report of SURMOUNT-OSA [5]Gastrointestinal events most frequent, mostly mild to moderateApnea-hypopnea index fell by 25.3 and 29.3 events/hour vs about 5 on placebo

Trials and records studies

A detailed analysis of the SURMOUNT-OSA questionnaires found that, after 52 weeks, people on tirzepatide reported better scores than placebo for sleep-related impairment, sleep disturbance, daily functioning and quality of life; in the trial without breathing machines, daytime sleepiness scores also improved. [6] These were people with sleep apnea, for whom better breathing at night is expected to help sleep, so the finding does not automatically carry over to everyone using Zepbound® for weight.

Real-world records give a less tidy picture. In a US electronic health record network, adults without type 2 diabetes who started tirzepatide had a slightly higher hazard of an insomnia diagnosis than those starting semaglutide (hazard ratio 1.13). [7] The authors note that their results remain subject to confounding and misclassified diagnoses. In adolescents with obesity, a separate records study found no significant difference in insomnia between incretin medicines, including tirzepatide, and lifestyle treatment. [8] Zepbound® is not approved for children, and neither study was a randomised trial.

What might be waking you

The label gives no mechanism for insomnia, because it does not describe insomnia. It does describe several things that can break up a night.

  • Reflux and indigestion. Both were more frequent on Zepbound® than on placebo, [1] and MedlinePlus notes that reflux symptoms can be worse after eating, when lying down and at night. [12]
  • Nausea and stomach upset during dose steps. Most nausea, vomiting and diarrhea occurred while the dose was being raised, then eased. [1] Each step comes after at least 4 weeks on the previous dose. [1]
  • Low blood sugar. In people with type 2 diabetes, especially those also taking a sulfonylurea or insulin, Zepbound® can cause low blood sugar, [1] and MedlinePlus lists trouble sleeping among its symptoms. [13]
  • Sleep apnea that is not yet controlled. The National Heart, Lung, and Blood Institute lists insomnia among sleep apnea symptoms, along with waking to urinate and morning headache. [9]

Causes that have nothing to do with the injection

MedlinePlus describes short-term insomnia as common and usually triggered by stress, family pressure or a difficult event. Ongoing insomnia is often a symptom of something else: medical conditions, medicines, other sleep disorders, or caffeine, tobacco and alcohol. [10] Depression, night or shift work and long-distance travel across time zones all raise the risk. [10]

Starting a weight treatment can bring several of these together: new routines, a changed meal pattern, more evening exercise, or worry about side effects. It is also worth reviewing any other medicine, supplement or diet product you take, which MedlinePlus specifically suggests asking about. [11]

Practical steps from general sources

The Zepbound® Medication Guide has no sleep-specific advice. It does allow the injection at any time of day and lets you shift your injection day provided 72 hours or more separate two doses, [2] which can help if the first day after a dose is your hardest; plan any change with your prescriber.

MedlinePlus’s sleep-habit guidance includes going to bed and getting up at about the same times, avoiding caffeine and alcohol in the evening, skipping heavy meals for at least 2 hours before bed, keeping the bedroom quiet and dark, and getting up to do something quiet if you cannot fall asleep within 30 minutes. [11] For night-time reflux it adds raising the head of the bed and eating dinner 2 to 3 hours before sleep. [12] Cognitive behavioural therapy is a recognised treatment for ongoing insomnia. [10] If you use a positive airway pressure machine, keep using it as prescribed: the Canadian patient information says Zepbound® does not replace it and that changes are your clinician’s call. [3]

Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help

SignWho to contactHow fastSource
Night sweats, shakiness, confusion or a pounding heart that wake you, especially on insulin or a sulfonylureaTreat as possible low blood sugar; tell your prescriberTodayMedication Guide [2]; MedlinePlus [13]
Severe stomach pain at night that will not go away, sometimes reaching the backStop Zepbound® and call your prescriber right awayTodayMedication Guide [2]
Feeling sad or depressed, or pain or discomfort keeping you awakeContact your health care providerAt your next appointmentMedlinePlus [11]
Loud snoring, gasping, morning headaches or daytime sleepiness despite treatmentDiscuss sleep apnea control with your clinicianAt your next appointmentNHLBI [9]
Insomnia lasting a month or longer, or using sleep medicines without adviceRaise at your next visitAt your next appointmentMedlinePlus [10][11]

Questions

Is insomnia a side effect of Zepbound®?

It is not listed in the US, Canadian or EU tirzepatide information. [1][3][4] One records study found slightly more insomnia diagnoses with tirzepatide than with semaglutide in adults without diabetes, but it cannot prove cause. [7]

I started Zepbound® for sleep apnea. Should my sleep improve?

In the SURMOUNT-OSA trials, people on Zepbound® reported less sleep-related impairment and sleep disturbance than with placebo after 52 weeks, alongside fewer breathing pauses. [1][5][6] Individual results vary; review progress with your sleep clinician.

Does injecting at night or in the morning matter for sleep?

No study has compared injection times for sleep. The label allows any time of day and lets you change the injection day if doses stay at least 72 hours apart. [1][2] Agree any change with your prescriber.

Heartburn keeps waking me on Zepbound®. Is that common?

Reflux was reported by 4–5% on Zepbound® versus 2% on placebo. [1] MedlinePlus suggests raising the head of the bed and eating dinner 2 to 3 hours before sleep. [12] Ask a pharmacist before using antacids.

Can I take a sleep aid while on Zepbound®?

MedlinePlus advises talking to your provider before taking sleep medicines. [11] Zepbound® slows stomach emptying and may affect how some oral medicines are absorbed, so check with your pharmacist too. [1]

I am not sleepless but sleepy all day. Is that Zepbound®?

Fatigue, which includes lethargy and malaise, was reported by 5–7% on Zepbound® versus 3% on placebo. [1] Daytime sleepiness is also a sleep apnea symptom, so mention it to your clinician. [9]

Sources

Sources checked on

  1. ZEPBOUND® (tirzepatide) Prescribing Information, Eli Lilly and Company Revised 08/2026. Sections 1, 2.1, 2.3, 5.7, 6.1 (Table 1, OSA trials), 7.2 and 14.2 (Table 8, sleep-related impairment).
  2. ZEPBOUND® (tirzepatide) Medication Guide, Eli Lilly and Company Revised 08/2026.
  3. ZEPBOUND® (tirzepatide injection) Product Monograph, Eli Lilly Canada Inc. Date of authorization 2026-06-11. Sections 4.1, 8.2 and 14 (SURMOUNT-OSA); patient medication information.
  4. Mounjaro (tirzepatide): EPAR – Product Information, European Medicines Agency Sections 4.8 and 5.1. No Zepbound® EPAR exists; tirzepatide is authorised in the EU as Mounjaro®.
  5. Malhotra A et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024 Two randomised phase 3 trials (SURMOUNT-OSA); PubMed abstract.
  6. Kanu C et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Med 2025 Prespecified trial outcomes; PubMed abstract.
  7. Huang YN et al. Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes. Commun Med 2026 Retrospective records study; PubMed abstract.
  8. Liu TH et al. Psychiatric safety of GLP-1 and dual GIP/GLP-1 receptor agonists in adolescents with obesity. Diabetes Obes Metab 2026 Retrospective cohort; PubMed abstract.
  9. Sleep Apnea: Symptoms, National Heart, Lung, and Blood Institute (NIH)
  10. Insomnia, MedlinePlus (U.S. National Library of Medicine)
  11. Changing your sleep habits, MedlinePlus Medical Encyclopedia
  12. Gastroesophageal reflux disease, MedlinePlus Medical Encyclopedia
  13. Low blood sugar, MedlinePlus Medical Encyclopedia

Set up your lab tonight.

It takes a few minutes. Pep will be waiting.